Comorbidities in the Spondyloarthritis GISEA Cohort : an average treatment effect analysis on patients treated with bDMARDs
OBJECTIVES: We aimed to investigate the effectiveness of tumour necrosis factor inhibitors (TNFi), anti-interleukin-17 or interleukin-12/23 monoclonal antibodies (anti-IL) on comorbidities in a cohort of patients with spondyloarthritis (SpA), using an average treatment effect (ATE) analysis.
METHODS: SpA patients from the multicentre Italian GISEA Registry were divided into groups according to pharmacological exposure: no treatment (G0), TNFi (G1) and non-responders to TNFi switched to anti-IL (G2). In each group, we recorded the prevalence and incidence of infectious, cardiopulmonary, endocrinological, gastrointestinal, oncologic, renal and neurologic comorbidities. Each comorbidity was then fitted for ATE and baseline features were evaluated for importance.
RESULTS: The main findings of this study comprising 4458 SpA patients relate to cancer, other gastrointestinal diseases (OGID) and fibromyalgia. ATE showed no increased risk of solid cancer in G1 (0.42 95% CI 0.20-0.85) and G2 (0.26 95% CI 0.08-0.71) vs. G0, with significantly higher incidence in G0 (14.07/1000 patient-years, p=0.0001). Conversely, a significantly higher risk of OGID and fibromyalgia was found in G1 (1.56 95% CI 1.06-2.33; 1.69 95% CI 1.05-2.68, respectively) and G2 (1.91 95% CI 1.05-3.24; 2.13 95% CI 1.14-3.41, respectively) vs. G0. No treatment risk reduction was observed in haematological malignancies, cardiovascular events and endocrinological comorbidities.
CONCLUSIONS: Overall, our study confirms the safety of TNFi and anti-IL in SpA patients, albeit with some caveats pertaining to solid cancers, OGID and fibromyalgia. Furthermore, taking into consideration causality with observational data may yield more reliable and relevant clinical information.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:42 |
|---|---|
| Enthalten in: |
Clinical and experimental rheumatology - 42(2024), 1 vom: 05. Jan., Seite 104-114 |
| Sprache: |
Englisch |
|---|
| Links: |
|---|
| Themen: |
Antirheumatic Agents |
|---|
| Anmerkungen: |
Date Completed 08.02.2024 Date Revised 08.02.2024 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.55563/clinexprheumatol/q38lu0 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM361481535 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM361481535 | ||
| 003 | DE-627 | ||
| 005 | 20240208231849.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.55563/clinexprheumatol/q38lu0 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1284.xml |
| 035 | |a (DE-627)NLM361481535 | ||
| 035 | |a (NLM)37650298 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Scagnellato, Laura |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Comorbidities in the Spondyloarthritis GISEA Cohort |b an average treatment effect analysis on patients treated with bDMARDs |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 08.02.2024 | ||
| 500 | |a Date Revised 08.02.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a OBJECTIVES: We aimed to investigate the effectiveness of tumour necrosis factor inhibitors (TNFi), anti-interleukin-17 or interleukin-12/23 monoclonal antibodies (anti-IL) on comorbidities in a cohort of patients with spondyloarthritis (SpA), using an average treatment effect (ATE) analysis | ||
| 520 | |a METHODS: SpA patients from the multicentre Italian GISEA Registry were divided into groups according to pharmacological exposure: no treatment (G0), TNFi (G1) and non-responders to TNFi switched to anti-IL (G2). In each group, we recorded the prevalence and incidence of infectious, cardiopulmonary, endocrinological, gastrointestinal, oncologic, renal and neurologic comorbidities. Each comorbidity was then fitted for ATE and baseline features were evaluated for importance | ||
| 520 | |a RESULTS: The main findings of this study comprising 4458 SpA patients relate to cancer, other gastrointestinal diseases (OGID) and fibromyalgia. ATE showed no increased risk of solid cancer in G1 (0.42 95% CI 0.20-0.85) and G2 (0.26 95% CI 0.08-0.71) vs. G0, with significantly higher incidence in G0 (14.07/1000 patient-years, p=0.0001). Conversely, a significantly higher risk of OGID and fibromyalgia was found in G1 (1.56 95% CI 1.06-2.33; 1.69 95% CI 1.05-2.68, respectively) and G2 (1.91 95% CI 1.05-3.24; 2.13 95% CI 1.14-3.41, respectively) vs. G0. No treatment risk reduction was observed in haematological malignancies, cardiovascular events and endocrinological comorbidities | ||
| 520 | |a CONCLUSIONS: Overall, our study confirms the safety of TNFi and anti-IL in SpA patients, albeit with some caveats pertaining to solid cancers, OGID and fibromyalgia. Furthermore, taking into consideration causality with observational data may yield more reliable and relevant clinical information | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Multicenter Study | |
| 650 | 7 | |a Antirheumatic Agents |2 NLM | |
| 650 | 7 | |a Tumor Necrosis Factor-alpha |2 NLM | |
| 700 | 1 | |a Collesei, Antonio |e verfasserin |4 aut | |
| 700 | 1 | |a Doria, Andrea |e verfasserin |4 aut | |
| 700 | 1 | |a Cozzi, Giacomo |e verfasserin |4 aut | |
| 700 | 1 | |a Lorenzin, Mariagrazia |e verfasserin |4 aut | |
| 700 | 1 | |a Atzeni, Fabiola |e verfasserin |4 aut | |
| 700 | 1 | |a Bugatti, Serena |e verfasserin |4 aut | |
| 700 | 1 | |a Caporali, Roberto |e verfasserin |4 aut | |
| 700 | 1 | |a Cauli, Alberto |e verfasserin |4 aut | |
| 700 | 1 | |a Conti, Fabrizio |e verfasserin |4 aut | |
| 700 | 1 | |a Corrado, Addolorata |e verfasserin |4 aut | |
| 700 | 1 | |a Carletto, Antonio |e verfasserin |4 aut | |
| 700 | 1 | |a Chimenti, Maria Sole |e verfasserin |4 aut | |
| 700 | 1 | |a Foti, Rosario |e verfasserin |4 aut | |
| 700 | 1 | |a Frediani, Bruno |e verfasserin |4 aut | |
| 700 | 1 | |a Gerli, Roberto |e verfasserin |4 aut | |
| 700 | 1 | |a Gorla, Roberto |e verfasserin |4 aut | |
| 700 | 1 | |a Govoni, Marcello |e verfasserin |4 aut | |
| 700 | 1 | |a Gremese, Elisa |e verfasserin |4 aut | |
| 700 | 1 | |a Guiducci, Serena |e verfasserin |4 aut | |
| 700 | 1 | |a Iagnocco, Annamaria |e verfasserin |4 aut | |
| 700 | 1 | |a Iannone, Florenzo |e verfasserin |4 aut | |
| 700 | 1 | |a Parisi, Simone |e verfasserin |4 aut | |
| 700 | 1 | |a Rossini, Maurizio |e verfasserin |4 aut | |
| 700 | 1 | |a Salaffi, Fausto |e verfasserin |4 aut | |
| 700 | 1 | |a Santo, Leonardo |e verfasserin |4 aut | |
| 700 | 1 | |a Sarzi Puttini, Piercarlo |e verfasserin |4 aut | |
| 700 | 1 | |a Sebastiani, Marco |e verfasserin |4 aut | |
| 700 | 1 | |a Semerano, Angelo |e verfasserin |4 aut | |
| 700 | 1 | |a Ferraccioli, Gianfranco |e verfasserin |4 aut | |
| 700 | 1 | |a Lapadula, Giovanni |e verfasserin |4 aut | |
| 700 | 1 | |a Ramonda, Roberta |e verfasserin |4 aut | |
| 700 | 0 | |a GISEA Study Group |e verfasserin |4 aut | |
| 700 | 1 | |a Bazzani, Chiara |e investigator |4 oth | |
| 700 | 1 | |a Bellando Randone, Silvia |e investigator |4 oth | |
| 700 | 1 | |a Cantatore, Francesco Paolo |e investigator |4 oth | |
| 700 | 1 | |a Congia, Mattia |e investigator |4 oth | |
| 700 | 1 | |a Favalli, Ennio Giulio |e investigator |4 oth | |
| 700 | 1 | |a Fusaro, Enrico |e investigator |4 oth | |
| 700 | 1 | |a Galoppini, Giorgio |e investigator |4 oth | |
| 700 | 1 | |a Garoffoni, Carlo |e investigator |4 oth | |
| 700 | 1 | |a Garufi, Cristina |e investigator |4 oth | |
| 700 | 1 | |a Lomater, Claudia |e investigator |4 oth | |
| 700 | 1 | |a Montecucco, Carlo Maurizio |e investigator |4 oth | |
| 700 | 1 | |a Salvarani, Carlo |e investigator |4 oth | |
| 700 | 1 | |a Siragusano, Cesare |e investigator |4 oth | |
| 700 | 1 | |a Striani, Giovanni |e investigator |4 oth | |
| 700 | 1 | |a Venerito, Vincenzo |e investigator |4 oth | |
| 700 | 1 | |a Visalli, Elisa |e investigator |4 oth | |
| 773 | 0 | 8 | |i Enthalten in |t Clinical and experimental rheumatology |d 1989 |g 42(2024), 1 vom: 05. Jan., Seite 104-114 |w (DE-627)NLM012613010 |x 0392-856X |7 nnns |
| 773 | 1 | 8 | |g volume:42 |g year:2024 |g number:1 |g day:05 |g month:01 |g pages:104-114 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.55563/clinexprheumatol/q38lu0 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 42 |j 2024 |e 1 |b 05 |c 01 |h 104-114 | ||